1197TiP A phase I-II multicenter, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors and dose-expansion in patients with non-small cell lung cancer harboring c-MET dysregulation - Lee, D.H.; Roohullah, A.; Cho, B.C.; Lee, S-H.; Lemech, C.; de Souza, P.; Millward, M.; Choi, J.; Park, K.E.; Kim, E.; Kim, N.Y.; Shin, Y.K.; et al. (Annals of Oncology, 2022)